Literature DB >> 11982723

Is severe liver disease a common outcome for people with chronic hepatitis C?

Gregory J Dore1, Anthony J Freeman, Matthew Law, John M Kaldor.   

Abstract

For people with chronic hepatitis C, an assessment of their risk of progression to advanced liver disease is a major priority. Early studies of the natural history of chronic hepatitis C suggested that development of cirrhosis was a relatively common outcome, even in the first 20 years of infection. These studies were either cross-sectional liver clinic series of people referred for assessment to specialist clinics, or longitudinal cohorts of people with post-transfusion hepatitis. More recent studies (particularly longitudinal community-based cohorts) indicate that liver disease progression is generally slow, and that a minority of people with chronic hepatitis C will develop advanced liver disease. Based on an extensive review of studies reporting on chronic hepatitis C natural history, we have developed a Markov model of liver disease progression. This model estimates that the risk of progression to cirrhosis is 7% and 20% after 20 and 40 years of infection, respectively. Corresponding estimates for hepatitis C-related mortality are 1% and 4%. However, liver disease progression is highly variable, and certain subgroups of people with chronic hepatitis C are at increased risk of advanced liver disease. Those groups include people with a heavy alcohol intake, those who have coinfection with HIV or HBV, and those who have already progressed to moderate to severe hepatic fibrosis. Copyright 2002 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Year:  2002        PMID: 11982723     DOI: 10.1046/j.1440-1746.2002.02730.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  17 in total

Review 1.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

Review 2.  Future therapies for chronic hepatitis C.

Authors:  Noura M Dabbouseh; Donald M Jensen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

3.  Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings.

Authors:  Sarah Larney; Madeline K Mahowald; Nicholas Scharff; Timothy P Flanigan; Curt G Beckwith; Nickolas D Zaller
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

4.  Is laparoscopy an advantage in the diagnosis of cirrhosis in chronic hepatitis C virus infection?

Authors:  Perdita Wietzke-Braun; Felix Braun; Peter Schott; Giuliano Ramadori
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

Review 5.  Regulation of hepatocyte fate by interferon-γ.

Authors:  Christopher J Horras; Cheri L Lamb; Kristen A Mitchell
Journal:  Cytokine Growth Factor Rev       Date:  2011-02-18       Impact factor: 7.638

6.  Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries.

Authors:  Bilal Ahmed; Tooba Ali; Huma Qureshi; Saeed Hamid
Journal:  Hepatol Int       Date:  2013-01-10       Impact factor: 6.047

7.  Interferon alpha induced intrahepatic pSTAT1 inversely correlate with serum HCV RNA levels in chronic HCV infection.

Authors:  Feyza Gunduz; Chaithanya Mallikarjun; Luis A Balart; Srikanta Dash
Journal:  Exp Mol Pathol       Date:  2013-11-08       Impact factor: 3.362

8.  "Seek, test, treat and retain" for hepatitis C in the United States criminal justice system.

Authors:  Sarah Larney; Curt G Beckwith; Nickolas D Zaller; Brian T Montague; Josiah Rich
Journal:  Int J Prison Health       Date:  2014

9.  Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Authors:  Uwe Siebert; Gaby Sroczynski; Pamela Aidelsburger; Siegbert Rossol; Jürgen Wasem; Michael P Manns; John G McHutchison; John B Wong
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment.

Authors:  Uwe Siebert; Gaby Sroczynski
Journal:  Ger Med Sci       Date:  2003-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.